Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM)

• Market cap: $5.76M
• 1 day: -13.29%
• 5 days: -28.40%
• 1 month: -40.36%
• 3 months: -27.36%
• 6 months: 1,569.45%
• Year to date: 233.33%
• 1 year: 214.14%
• 5 years: -60.42%
• 10 years: -60.42%

About: Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.

Employees: 8

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

3.7% more ownership

Funds ownership: 0% [Q2] → 3.7% (+3.7%) [Q3]

8% less capital invested

Capital invested by funds: $159K [Q2] → $146K (-$12.8K) [Q3]

20% less funds holding

Funds holding: 15 [Q2] → 12 (-3) [Q3]

50% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 6

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 8